Perioperative ivonescimab with or without chemotherapy in resectable non-small cell lung cancer: a phase 2 trial
In a nonrandomized phase 2 trial, patients with resectable non-small cell lung cancer received perioperative ivonescimab as monotherapy or with chemotherapy, leading to encouraging pathological response rates in both cohorts, and sustained circulating tumor DNA negativity throughout neoadjuvant therapy may be predictive of response.
Authors
- Huilai Lv (ORCID: https://orcid.org/0000-0003-2574-7891)
- Huang Wuhao
- Zhenfa Zhang (ORCID: https://orcid.org/0000-0002-9627-2590)
- Bin Jia (ORCID: https://orcid.org/0000-0002-3712-9225)
- Zhongmin Maxwell Wang (ORCID: https://orcid.org/0000-0002-1683-5147)
- Jun-Ye Zhang (ORCID: https://orcid.org/0009-0006-3829-603X)
- Boning Li (ORCID: https://orcid.org/0009-0008-7278-2925)
- Dongsheng Yue (ORCID: https://orcid.org/0000-0002-4937-7525)
- Michelle Xia (ORCID: https://orcid.org/0000-0002-5137-2002)
- Qiang Zhang (ORCID: https://orcid.org/0000-0001-7046-4378)
- Yue Li (ORCID: https://orcid.org/0000-0001-8198-9911)
- Yu Zhang (ORCID: https://orcid.org/0000-0001-8066-7275)
- Changli Wang (ORCID: https://orcid.org/0000-0003-1075-5071)
- Shiwang Wen
- Chong Pang
- Yao Tang
- Shengguang Wang
- Ziqiang Tian
- Chenguang Li
- Lianmin Zhang
- Jianquan Zhu
- Bin Zhang
- Wenting Li
- Hui Chen
- Meng Wang
- Hua Zhang
- Sha Wang
- Xiaoliang Zhao (ORCID: https://orcid.org/0009-0000-7207-6555)
- Xiaofei Wang
- Chen Chen
- Wei Wei
Institutions
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Fourth Hospital of Hebei Medical University (CN)
Publication Details
- Journal
- Nature Medicine
- Published
- 2026-11-04
- DOI
- https://doi.org/10.1038/s41591-026-04745-4
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00